priya rastogi, md, considers the interchangeability of cdk 4/6 inhibitors
Published 3 years ago • 73 plays • Length 1:06
Download video MP4
Download video MP3
Similar videos
-
0:36
priya rastogi, md, on key takeaways for oncologists regarding the tolerability of cdk 4/6 inhibitors
-
0:59
priya rastogi, md, shares the design and outcomes of the monarche clinical trial from sabcs 2020
-
0:41
priya rastogi, md, elaborates on the role of abemaciclib in hr , her2- node positive breast cancer
-
1:09
priya rastogi, md, provides details on the subgroup of patients with ki-67 status from monarche
-
2:21
erika hamilton, md, regarding the use of cdk 4/6 inhibitors in clinical practice
-
1:40
debu tripathy, md, regarding cdk 4/6 inhibitors in the treatment of breast cancer
-
4:50
hope rugo, md, provides perspective on the clinical progress of cdk 4/6 inhibitors in breast cancer
-
1:02:43
realizing the potential of cdk 4/6 inhibitor therapy in breast cancer: real-world data and evidence
-
14:51
expert perspectives: targeting advanced er metastatic breast cancer with cdk 4/6 inhibitors
-
17:54
expert perspectives: cdk 4/6 inhibitors for er breast cancer: current data and clinical use
-
3:57
cdk 4/6 inhibitor as first-line therapy for advanced breast cancer
-
3:27
metastatic breast cancer: cdk4/6 inhibitors
-
1:47
dr. tripathy on combination strategies with cdk4/6 inhibitors in breast cancer
-
1:21
dr. tripathy on combination strategies with cdk4/6 inhibitors in hr breast cancer
-
2:31
cdk4/6 inhibitors: a hot topic in breast cancer treatment
-
5:34
cdk4/6 inhibitors in metastatic breast cancer
-
3:27
metastatic breast cancer: cdk4/6 inhibitors
-
0:22
copy of dr. tripathy on combination strategies with cdk4/6 inhibitors in hr breast cancer
-
2:02
metastatic breast cancer treatments in development
Clip.africa.com - Privacy-policy